Lucid Diagnostics, Subsidiary of PAVmed, Secures Medicare Reimbursement and Closes $15 Million Financing

Article summary

Lucid Diagnostics Inc., a majority-owned subsidiary of PAVmed Inc., has begun receiving Medicare reimbursement for its EsoGuard® Esophageal DNA Test and completed a $15 million private placement of Series C Convertible Preferred Stock.